ResourceDrug Discovery & Development
AstraZeneca Enhances Drug Discovery with Pelago Bioscience's CETSA® Assay
5 Jul 2024Pelago Bioscience offers high-throughput screening service based on CETSA® - a transformative, label-free assay for target engagement quantification in physiologically relevant context. In this case study, the CETSA® assay has been exemplified with AstraZeneca's screening of 500,000 compounds on a protein target, demonstrating superior hit rates and a six-month time-saving advantage.
Related Products
Request Quote for All Products
Primary Screening with CETSA
Pelago BiosciencePrimary screening based on Cellular Thermal Shift Assay (CETSA) allows for rapid identification of high quality chemical starting points against the native, full-length protein in live cells.